Capecitabine
Pancreatic Ductal Adenocarcinoma
Explore 280 assets in Pancreatic Ductal Adenocarcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07233850CT.gov A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | — | Not Yet Recruiting | — | — | — |
NCT07024615CT.gov A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | — | Recruiting | — | — | — |
NCT07020221CT.gov A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT06831136CT.gov Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma | — | Recruiting | — | — | — |
NCT06813079CT.gov Using Tumor Models to Determine Treatments | — | Not Yet Recruiting | — | — | — |
NCT05867121CT.gov A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 | — | Completed | — | — | — |
NCT05482893CT.gov Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | — | Recruiting | — | — | — |
NCT05431270CT.gov Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | — | Recruiting | — | — | — |
NCT04990609CT.gov EUS-RFA PANCARDINAL-1 Trial | — | Recruiting | — | — | — |
NCT02981342CT.gov A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT01836432CT.gov Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer | — | Terminated | — | — | — |
NCT01394120CT.gov Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | Shenyang Sunshine Pharmaceutical Co., LTD. | P3 | B · 62 |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | BB |
| S-1 | Genentech, Inc. | P2 | BB |
| Ivospemin | Panbela Therapeutics, Inc. | P2/3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Metformin | British Columbia Cancer Agency | P2 | BB |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DaraxonrasibRevolution Medicines, Inc.BB
- Rmc-6236Tango Therapeutics, Inc.BB
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteBB
- S-1Genentech, Inc.BB
- IvospeminPanbela Therapeutics, Inc.BB
Citation
Floatz Terminal. Capecitabine in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →